#ES­MO24 roundup: New da­ta on Am­gen’s PRMT5 in­hibitor seem lack­lus­ter, and Jazz’s HER2 an­ti­body

On Sun­day evening, ab­stracts from the Eu­ro­pean So­ci­ety for Med­ical On­col­o­gy were re­leased. While some of on­col­o­gy’s most ex­cit­ing re­cent da­ta were …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA